BIIX 1 XX inhalation solution
Drugsingle doses of 800, 1000, 1200, 1400, 1600, 1800, or 2000 mcg
NCT Number: NCT02198287
Safety, tolerability and pharmacokinetic study of BIIX 1 XX in healthy male volunteers.
Looking for future studies?
Notify Me21 year–50 year
Male
Interventional
Phase 1
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
single doses of 800, 1000, 1200, 1400, 1600, 1800, or 2000 mcg
Time frame: up to 22 days
Time frame: up to 8 days after drug administration
Time frame: up to 8 days after drug administration
Time frame: pre-dose, 10 and 30 minutes after administration
Time frame: pre-dose, 10 and 30 minutes after administration
Time frame: up to 8 days after drug administration
Time frame: up to 168 hours after drug administration
Time frame: up to 168 hours after drug administration
Time frame: up to 168 hours after drug administration
Time frame: up to 168 hours after drug administration
Boehringer Ingelheim
Industry
A Single Increasing Dose Safety and Tolerability Study (Dose Extension) After Inhalational Administration of BIIX 1 XX (Single Doses: 800 - 2000 mcg) in Healthy Young Male Volunteers (Randomised, Double-blind, Placebo-controlled)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details